US regulators are still on the fence about cryptocurrencies. The US Securities and Exchange Commission (SEC) has begun to approve bitcoin-themed exchange-traded funds (ETFs), but with important caveats. Last week the SEC gave the nod to the Volt Crypto Industry Revolution and Tech ETF, says Hassan Maishera on FXEmpire. The ETF will offer investors exposure to some of the leading crypto firms on the market, such as Nasdaq-listed MicroStrategy. But the SEC has still yet to approve any cryptocurrency ETF “that seeks to directly track the performance of bitcoin”.
Investors use ETFs to track the performance of assets such as gold or equities, says Nathan Reiff on Investopedia. For all the hype, bitcoin remains difficult to invest in, requiring investors to turn to specialised exchanges and deal with “complex storage and security procedures”. A bitcoin ETF would allow a much larger pool of investors to buy bitcoin in the same way and on the same platforms where they trade stocks.
The approval of “bitcoin lite” ETFs such as Volt is a “sop” to investors, says Steve Johnson in the Financial Times. US regulators are still refusing to approve any ETFs “that invest in the cryptocurrency itself”, even though similar vehicles have already been launched in Canada and parts of Europe. SEC chair, Gary Gensler, has called cryptocurrencies a “wild west” and an “asset class…rife with fraud, scams and abuse”.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Can I shield my ISAs from inheritance tax?Many investors and savers will be wondering if there’s anything they can do to protect their ISAs from inheritance tax, especially as pensions will become liable for the levy from April 2027. We reveal the options available to ISA customers
-
What is the average salary by age – and how do you compare?Are you making more than your peers? We look at the average salary by age to see how much the typical Brit earns at different stages of their life
-
BP's 'long, painful decline' – and why next year could be even tougherOpinion Long-suffering shareholders in oil giant BP have been pushing for change. It won’t come soon enough, says Matthew Lynn
-
Investment trusts tap the profits in exotic and obscure global marketsOpinion Peter Walls, manager of the Unicorn Mastertrust fund, highlights three investment trusts as he shares where he'd put his money
-
Falling revenues and mounting debt spell trouble for Jumia TechnologiesStruggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
-
Best of British bargains: cash in on undervalued companies in the UK stock marketOpinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
-
Building firm Keller presents low debt and ample scope for growthGeotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
-
PZ Cussons share price down 75% in last decade – why it's one to watchOpinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharmaOpinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
